Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
Related Questions
Would you switch to a TNF-I if patient developed squamous cell skin cancer on Orencia after failure of MTX for seropositive RA?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?
How do you approach restarting cDMARDS/bDMARDS in a patient with active RA after incidence of disseminated CNS VZV infection while on tofacitinib?
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
What is your approach to biologic therapy in older adults (80+) and CKD with RA?
